HMG-CoA reductase inhibitors (statins) are the mainstay in the pharmacologic management
of dyslipidemia. Since they are widely prescribed, their safety remains an issue of concern …

Background—Statins are currently the mainstay of dyslipidemia management for the primary
and secondary prevention of cardiovascular disease. Controversial concerns about the …

Background: The safety and tolerability of rosuvastatin were assessed using data from
16,876 patients who received rosuvastatin 5–40 mg in a multinational phase II/III/IIIb/IV …

Background Although the effectiveness of statins is well established, analyses of
spontaneous adverse event reports have recently questioned the safety of rosuvastatin …

Introduction: Statins are the cornerstone of lipid-lowering therapy to reduce the risk of
coronary heart disease. Rosuvastatin and pitavastatin are the two recently developed statins …

Introduction: Rosuvastatin is a highly efficacious statin approved for use throughout the
world. Rosuvastatin has been exhaustively evaluated in the setting of a broad variety of …

The safety and tolerability of rosuvastatin were assessed (as of August 2003) using data
from 12,400 patients who received 5 to 40 mg of rosuvastatin in a multinational phase II/III …

Purpose The purpose of this study was to compare incidence rates of hospitalization
associated with rhabdomyolysis, myopathy, renal, or hepatic dysfunction, and of in‐hospital …

Rosuvastatin is the first statin approved by the regulatory authorities since the withdrawal of
cerivastatin. Although highly efficacious, this new statin has generated considerable …

The risks of muscle adverse events related to use of the 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase inhibitors, or statins, increase significantly with the …